{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:38:05Z","timestamp":1649155085484},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bulcan.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T19:01:56Z","timestamp":1523646116000},"page":"331-332","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Obligation de d\u00e9pistage du d\u00e9ficit en DPD avant prescription de fluoropyrimidines"],"prefix":"10.1016","volume":"105","author":[{"given":"Nicolas","family":"Penel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1684\/bdc.2011.1476","article-title":"Antimetabolites","volume":"98","author":"Lansiaux","year":"2011","journal-title":"Bull Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.bulcan.2018.03.001_bib0010","first-page":"154","article-title":"Cardiotoxicit\u00e9 du 5\u00a0fluorouracile","volume":"91","author":"Teixeira","year":"2004","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2018.03.001_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabin toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2018.03.001_bib0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"D\u00e9pistage du d\u00e9ficit en dihydropyrimidine deshydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u00a0: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2018.03.001_bib0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","article-title":"Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?","volume":"28","author":"Mercier","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.bulcan.2018.03.001_bib0030","doi-asserted-by":"crossref","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DYPD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.bulcan.2018.03.001_bib0035","unstructured":"Compte-rendu du comit\u00e9 technique de pharmacovigilance de l\u2019ANSM du 28\u00a0mars 2017. (CR-CT012017033_pharmacovigilance-mars2017)."},{"key":"10.1016\/j.bulcan.2018.03.001_bib0040","unstructured":"Point d\u2019information actualis\u00e9 du 28\u00a0f\u00e9vrier 2018. http:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Prevention-des-effets-indesirables-graves-lies-a-un-deficit-en-dihydropyrimidine-deshydrogenase-DPD-lors-de-traitement-par-fluoropyrimidines-5-fluorouracile-et-capecitabine-Point-d-information-actualise-au-28-fevrier-2018."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118300961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118300961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T20:00:56Z","timestamp":1571169656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118300961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0007455118300961"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.03.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obligation de d\u00e9pistage du d\u00e9ficit en DPD avant prescription de fluoropyrimidines","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}